MiMedx Group(NASDAQ) MDXG

MiMedx helps people heal using tissue from human placentas. Doctors use these products to treat difficult skin wounds and surgical sites. They help patients recover from burns and chronic sores.

Healing Products for Every Need

• Surgical: Tissues used in operating rooms to close wounds and protect body parts; generated $36 million in net sales in Q1 2026.
• Wound: Membranes applied to chronic, non-healing sores like diabetic ulcers; generated $23 million in net sales in Q1 2026.
• Placental Allografts: Tissue transplants like EpiFix and AmnioFix that provide a protective barrier for internal and external healing.
• RegenKit-Wound Gel: New distribution product used to help prepare skin for healing treatments.

Expanding Through New Deals

• Acquired exclusive rights from TELA Bio, Inc. in March 2024 to sell a collagen-based surgical product in the United States.
• Invested $2 million in Vaporox, Inc. during 2025 through a convertible note agreement to support new wound healing technology.
• Paid $5 million to Regen Lab USA LLC in January 2026 for the exclusive right to distribute their wound gel product.
• Launched two new products, AMNIOFIX Thyroid Shields and CHORIOFIX, during the first quarter of 2026.
• Partnered with Summit Products Group in early 2026 to distribute several new surgical products including G4Derm Plus and Novaform.

The MiMedx Difference

The company uses its proprietary PURION process to clean and preserve human tissue while keeping its natural healing properties. Every product undergoes terminal sterilization, a process that ensures the tissue is safe and free of germs before use in patients.

First Quarter Performance Highlights

• Net sales fell to $59 million in Q1 2026, down 33.1% from $88 million in Q1 2025.
• Net income dropped to a $10.9 million loss in Q1 2026, which worsened from a $7.0 million profit in Q1 2025.
• Cash and cash equivalents reached $160 million by March 31, 2026, an increase of $53 million compared to the prior year.
• Operating cash flow was $1.9 million for the quarter ended March 31, 2026, down 64.5% from $5.3 million in the same period of 2025.
• Wound segment sales decreased 59.7% year-over-year in Q1 2026 following changes to Medicare reimbursement rules.

Bottom Line

MiMedx is shifting its focus toward surgical applications as it manages a difficult transition in the wound care market. The company is using its strong cash position to add new products through partnerships and internal development to diversify its business.